Citadel Advisors’s Boundless Bio BOLD Stock Holding History

Citadel Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$363K	Sell	145,049 -1,197,082	-89%	-$1.84M	﹤0.01%	10677
2026 Q1	$1.48M	Sell	1,342,131 -11,773	-0.9%	-$13.8K	﹤0.01%	6743
2025 Q4	$1.62M	Buy	1,353,904 +477,492	+54%	+$595K	﹤0.01%	6334
2025 Q3	$1.08M	Buy	876,412 +45,476	+5%	+$52.5K	﹤0.01%	7379
2025 Q2	$839K	Hold	830,936	–	–	﹤0.01%	7473
2025 Q1	$1.25M	Buy	830,936 +40,297	+5%	+$83.5K	﹤0.01%	6453
2024 Q4	$2.29M	Buy	790,639 +72,112	+10%	+$210K	﹤0.01%	5344
2024 Q3	$2.49M	Hold	718,527	–	–	﹤0.01%	5114
2024 Q2	$2.73M	Sell	718,527 -136,277	-16%	-$1.3M	﹤0.01%	4750
2024 Q1	$12M	Buy	+854,804	New	+$12.2M	﹤0.01%	2696

Other funds holding BOLD

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Citadel Advisors's BOLD Position: Q2 2026 in Review

Citadel Advisors reduced its Boundless Bio (BOLD) stake by 89% in Q2 2026, selling an estimated $1.84M and leaving 145,049 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #10677.

Citadel Advisors first reported a position in BOLD in Q1 2024 and has held it in 10 quarters since. The position peaked at $12M in Q1 2024. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

Citadel Advisors held 145,049 shares of Boundless Bio worth $363K as of Q2 2026.
Citadel Advisors sold 1,197,082 Boundless Bio shares in Q2 2026, an estimated $1.84M.
Boundless Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10677 holding.
Citadel Advisors first reported a position in Boundless Bio in Q1 2024 and has held it in 10 quarters since.
Citadel Advisors's Boundless Bio position peaked at $12M in Q1 2024.
40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.